Visugromab in Cachexia International Trial
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
CatalYm GmbH
518 participants
Apr 16, 2026
INTERVENTIONAL
Conditions
Summary
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Eligibility
Inclusion Criteria2
- Weight loss
- Advanced cancer
Exclusion Criteria1
- Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigational product
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
High dose
IV infusion
Medium dose
Low dose
Locations(35)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07112196